interventionelle, medikamentöse Studien
Titel
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Indikation
High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC)
Art der Studie
Therapiestudie, interventionell, Phase 3
Einschlusszeitpunkt
Zweitlinientherapie
Hauptprüfer am Zentrum (PI)
Prof. Dr. med. G. Gakis
Ansprechpartner
K. Biermann
Telefon: 0345/ 557 5810
Mail: karoline.biermann@uk-halle.de
Titel
A Phase 2, Randomized, Double-blind, Placebo- and Active-comparatorcontrolled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection
Indikation
High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection
Art der Studie
Therapiestudie, interventionell, Phase 2
Einschlusszeitpunkt
Zweitlinientherapie
Hauptprüfer am Zentrum (PI)
Prof. Dr. med. G. Gakis
Ansprechpartner
K. Biermann
Telefon: 0345/ 557 5810
Mail: karoline.biermann@uk-halle.de